PipelineRisk
An AI dashboard that scores clinical-trial failure risk for every drug in a pharma pipeline, using decades of public trial data to flag which candidates are likely to fail and why.
Biotech and pharma investors evaluating pipeline risk
- Per-trial failure-risk score based on indication, phase, sponsor history, and trial design
- Historical failure-rate benchmarks by therapeutic area and trial phase
- Plain-language red-flag explanations for each tracked drug
- Email alerts when a tracked drug's risk profile changes
Clinical failure rates over the decades are drawing fresh scrutiny on HN; biotech investors increasingly need data-driven ways to separate real breakthroughs from risky pipelines.
Moderate real demand: HN post had only 12 points/8 comments, but BioPhy raised $4.5M specifically for AI clinical-trial success prediction and Biomedtracker/Citeline already monetize clinical probability-of-success scores to investors.Backed by $4.5M raise, BioPhy is using AI to predict successful clinical trials ↗The Biotech Investor Tools Stack: 25 Platforms Powering Life Science Investment Decisions in 2026 ↗
Very crowded: Evaluate Pharma, Clarivate/Cortellis, GlobalData, Citeline/Biomedtracker (already sells clinical probability-of-success scores), BioCentury, BioPhy, AuraPharma and Widelly all serve overlapping needs for pharma/biotech investors.The Biotech Investor Tools Stack: 25 Platforms Powering Life Science Investment Decisions in 2026 ↗Cortellis Clinical Trials Intelligence - Clarivate ↗
Strong willingness to pay: enterprise pharma-intel tools (Cortellis, Evaluate, Biomedtracker) command high six/seven-figure contracts from funds and BD teams, and BioPhy has funded a $4.5M build on this exact value prop.Backed by $4.5M Raise, BioPhy is Using AI to Predict Successful Clinical Trials ↗Evaluate Pharma | Consensus Forecasts | Evaluate ↗
Durable: clinical drug development, FDA regulation and investor due diligence are structural, decade-spanning activities; clinical failure rates are a permanent concern regardless of AI hype cycles.Enhancing clinical trial outcome prediction with artificial intelligence ↗
Moderate: public data (ClinicalTrials.gov, FDA, publications) and off-the-shelf ML are accessible, but credible failure-risk scoring requires validated phase-by-phase benchmarks, domain expertise, and trust-building with pharma data — non-trivial for a startup.TrialBench: Multi-Modal AI-Ready Datasets for Clinical Trial Prediction ↗How AI Will Predict Clinical Trial Failures Before They Happen 2025 ↗